Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590.
   PubMed Web of Science ®Google Scholar
• Suvannasarn R, Muangmool T, Wongpakaran N, et al. Health-related quality of life for early-stage cervical cancer survivors after primary radical surgery followed by radiotherapy versus radical surgery alone. J Obstet Gynaecol. 2022;42(5):1217–1224.
   PubMedGoogle Scholar
• Stanca M, Căpîlna DM, Trâmbițaș C, et al. The overall quality of life and oncological outcomes following radical hysterectomy in cervical cancer survivors results from a large long-term single-institution study. Cancers. 2022;14(2):317.
   Web of Science ®Google Scholar
• Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393(10167):169–182.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao Y, Tu Q, et al. The roles of programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy. Curr Med Chem. 2021;28(5):893–909.
   PubMed Web of Science ®Google Scholar
• Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv262.
   PubMed Web of Science ®Google Scholar
• Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN guidelines insights: cervical cancer, version 1. J Natl Compr Canc Netw. 2020;18(6):660–666.
   PubMed Web of Science ®Google Scholar
• Marret G, Borcoman E, Le Tourneau C. Pembrolizumab for the treatment of cervical cancer. Expert Opin Biol Ther. 2019;19:871–877.
   PubMed Web of Science ®Google Scholar
• De Felice F, Giudice E, Bolomini G, et al. Pembrolizumab for advanced cervical cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021;21(2):221–228.
   PubMed Web of Science ®Google Scholar
• Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–1867.
   PubMed Web of Science ®Google Scholar
• Prasad V, Kim C, Burotto M, et al. The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med. 2015;175(8):1389–1398.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Paoletti X, Lewsley LA, Daniele G, et al. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1918939.
   PubMed Web of Science ®Google Scholar
• Ferguson JS, Summerhayes M, Masters S, et al. New treatments for advanced cancer: an approach to prioritization. Br J Cancer. 2000;83(10):1268–1273.
   PubMed Web of Science ®Google Scholar
• Godman B, Hill A, Simoens S, et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):527–540.
   PubMed Web of Science ®Google Scholar
• Al-Ziftawi NH, Shafie AA, Mohamed Ibrahim MI. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):655–666.
   PubMed Web of Science ®Google Scholar
• DeMartino PC, Miljkovic MD, Prasad V. Potential cost implications for all US food and drug administration oncology drug approvals in 2018. JAMA Intern Med. 2021;181(2):162–167.
   PubMed Web of Science ®Google Scholar
• Shi Y, Chen J, Shi B, et al. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer. Gynecol Oncol. 2022;164(2):379–385.
   PubMed Web of Science ®Google Scholar
• Barrington DA, Riedinger C, Haight PJ, et al. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: a cost-effectiveness analysis. Gynecol Oncol. 2022;165(3):500–505.
   Web of Science ®Google Scholar
• Yue X, Li Y, Wu J, et al. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1–5.
   PubMedGoogle Scholar
• Kazibwe J, Gheorghe A, Wilson D, et al. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-Income countries from 2015 to 2020: a review. Value Health. 2022;25(3):385–389.
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Kreif N, Benedict A, et al. Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics. 2013;31(8):663–675.
   PubMed Web of Science ®Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics. 2014;32:101–108.
   PubMed Web of Science ®Google Scholar
• Liu GG, Wu H, Li M, et al. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17(5):597–604.
   PubMed Web of Science ®Google Scholar
• Zhang B, Long EF. Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Res Treat. 2019;175(3):775–779.
   PubMed Web of Science ®Google Scholar
• YaoZH. Drug pice; 2022 [accessed 2022 Aug 18]. Available from: https://www.yaozh.com/
   Google Scholar
• Wu B, Dong B, Xu Y, et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One. 2012;7:e32530.
   PubMed Web of Science ®Google Scholar
• Chou TC, Chiang SC, Ko Y. Health state utilities for metastatic breast cancer in Taiwan. Breast. 2020;51:57–64.
   PubMed Web of Science ®Google Scholar
• Kang S, Wang X, Zhang Y, et al. First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a network meta-analysis and cost-effectiveness analysis. Front Oncol. 2021;11:740091.
   PubMed Web of Science ®Google Scholar
• Qiao L, Zhou Z, Zeng X, et al. Cost-effectiveness of domestic PD-1 inhibitor camrelizumab combined with chemotherapy in the first-line treatment of advanced nonsquamous non-small-cell lung cancer in China. Front Pharmacol. 2021;12:728440.
   PubMed Web of Science ®Google Scholar
• Dyer BA, Zamarin D, Eskandar RN, et al. Role of immunotherapy in the management of locally advanced and recurrent/metastatic cervical cancer. J Natl Compr Canc Netw. 2019;17(1):91–97.
   PubMed Web of Science ®Google Scholar
• Wendel Naumann R, Leath CA 3rd. Advances in immunotherapy for cervical cancer. Curr Opin Oncol. 2020;32(5):481–487.
   PubMed Web of Science ®Google Scholar
• Sherer MV, Kotha NV, Williamson C, et al. Advances in immunotherapy for cervical cancer: recent developments and future directions. Int J Gynecol Cancer. 2022;32(3):281–287.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials. Cancer Treat Rev. 2022;106:102385.
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021;3:100060.
   PubMedGoogle Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601–609.
   PubMed Web of Science ®Google Scholar
• Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac J Cancer Prev. 2015;16(17):7401–7407.
   PubMedGoogle Scholar
• Ueda Y, Miyagi E. Importance of education about cervical cancer and its preventive measures for the promotion of HPV vaccine according to the WHO strategies. Vaccines. 2021;9(10):1199.
   Web of Science ®Google Scholar